Контактная информация

Соискатель указал эл. почту.

Получить контакты этого кандидата можно на странице https://www.work.ua/resumes/5278226/

Опыт работы

CRA II

с 04.2016 по 04.2019 (3 года)
PPD, Kyiv (медицина\фармацевтика)

CRA

с 12.2003 по 03.2013 (9 лет 3 месяца)
VCR, Kyiv (медицина\фармацевтика)

Образование

КНТЕУ

Экономика предприятия, Київ
Высшее, с 2002 по 2008 (5 лет 9 месяцев)

Дополнительная информация

EDUCATION


Specialist in Economic of Enterprises, 2010
Kyiv National University of Trade and Economics, Ukraine

Specialist Dental Technician, 1997
Kyiv Medical College #4, Ukraine

WORK EXPERIENCE

2016 – 2019 CRA II
2015 – 2016 Senior lab assistant
2004 – 2013 Clinical research associate
2001 – 2003 Technical assistant to director
2000 – 2004 Sales manager
1996 – 1999 Dental technician


THERAPEUTIC EXPERIENCE

Nervous System/Sense Organs: Multiple Sclerosis – 2016-2019
Circulatory: Heart Failure, Coronary Artery Disease (CAD) – 2005-2011
Musculoskeletal: Osteoarthritis and Rheumatoid Arthritis – 2008-2009
Oncology: Breast Cancer, Chronic Lymphocytic Leukaemia (CLL) – 2011-2013
CLINICAL TRIAL EXPERIENCE

Circulatory: A randomized, double-blind, placebo-controlled study for Systolic Heart Failure Treatment with the lf Inhibitor Ivabradine.

Circulatory: A randomized, double-blind, placebo-controlled study of Eplerenone in Chronic Heart Failure, mild hospitalized and survival study patients with Heart Failure.

Circulatory: An international, multi-center, randomized, double-blind study to compare Ivabradine with placebo in reducing mortality and cardiovascular events in patients with stable Coronary Artery Disease (CAD) and Left Ventricular Systolic Dysfunction.

Circulatory: A study assessing the morbidity-mortality benefits of the If Inhibitor Ivabradine in patients with Coronary Artery Disease (CAD).

Musculoskeletal: A multi-center, double-blind, parallel-group, placebo-controlled study of the efficacy and safety of IMP in patients with Osteoarthritis and Rheumatoid Arthritis.

Nervous System/Sense Organs: A phase III, safety and efficacy study evaluating the use of IMP for the treatment of Relapsing Multiple Sclerosis.

Nervous System/Sense Organs: A Multicenter, Open-Label, Extension Study to Evaluate the
Long-Term Safety and Efficacy of DAC HYP Monotherapy in Subjects With Multiple Sclerosis.

Nervous System/Sense Organs: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of IP in patients with MS.

Oncology: A phase III, double-blind, randomized, parallel-group, active-controlled study to compare the efficacy and safety of IMP in patients with Early Breast Cancer.

Oncology: A phase III, open-label, randomized study of Ofatumumab added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide combination in patients with Relapsed Chronic Lymphocytic Leukaemia (CLL).